Latest News and Press Releases

AVITA Medical receives FDA approval for RECELL GO mini, optimizing treatment for smaller wounds and expanding patient accessibility.

AVITA Medical announces FDA clearance for Cohealyx, a new collagen-based dermal matrix, expanding its addressable market.

AVITA Medical to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.

VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care...

AVITA Medical announces exclusive distribution agreement to expand the RECELL product platform to Australia and New Zealand.

AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on November 12, 2024.

AVITA Medical reported third-quarter commercial revenue of $19.5 million, reflecting an approximately 44% increase over the same period last year.

AVITA Medical announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on November 7, 2024.

AVITA Medical to present at the 2024 Cantor Global Healthcare Conference on September 18, 2024, at 9:10 a.m. Eastern Time.

AVITA Medical will participate in Lake Street Capital Markets’ 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024.